Nikola Matejkova

Nikola Matejkova

Auto-generated profile, based on publicly available information

Nikola Matejkova

University of Pardubice

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2024 in Biomacromolecules
Verified
Journal Article
Open access
NMNikola Matějková
Nikola Matějková
LKLucie Korecka
Lucie Korecka
Petr ŠálekPetr Šálek
Petr Šálek
OKOlga Kočková
Olga Kočková
EPEwa Pavlova
Ewa Pavlova
ZBZuzana Bílková
Zuzana Bílková
Hyaluronic acid is an excellent biocompatible material for in vivo applications. Its ability to bind CD44, a cell receptor involved in numerous biological processes, predetermines HA-based nanomaterials as unique carrier for therapeutic and theranostic applications. Although numerous methods for the synthesis of hyaluronic acid nanoparticles (HANPs) are available today, their low reproducibility and wide size distribution hinder the precise assessment of the effect on the organism. A robust and reproducible approach for producing HANPs that meet strict criteria for in vivo applications (e.g., to lung parenchyma) remains challenging. We designed and evaluated four protocols for the preparation of HANPs with those required parameters. The HA molecule was cross-linked by novel combinations of carbodiimide, and four different amine-containing compounds resulted in monodisperse HANPs with a low polydispersity index. By a complex postsynthetic characterization, we confirmed that the prepared HANPs meet the criteria for inhaled therapeutic delivery and other in vivo applications.

6 September 2024 in Microchemical Journal
Verified
Journal Article
Closed access
NMNikola Matejkova
Nikola Matejkova
DSDenisa Smela
Denisa Smela
MBMartin Beranek
Martin Beranek
JCJan Capek
Jan Capek
LMLucie Michalcova
Lucie Michalcova
ZBZuzana Bilkova
Zuzana Bilkova

21 July 2025 in ACS Omega
Verified
Journal Article
Open access
ZSZuzana Svobodova
Zuzana Svobodova
LKLucie Krizova
Lucie Krizova
NMNikola Matejkova
Nikola Matejkova
DSDenisa Smela
Denisa Smela
MBMartin Beranek
Martin Beranek
Burkhard HorstkotteBurkhard Horstkotte
Burkhard Horstkotte
We present the first automated synthesis of magnetic immunosorbents (MIS) using a lab-in-syringe (LIS) platform, facilitating antibody bioconjugation to magnetic beads via carbodiimide-mediated covalent binding. This approach is an efficient, reproducible alternative to traditional manual methods, minimizing pipetting steps, vortexing, and incubation with a reduced handling bias. Utilizing a 1 mL syringe pump with a 12-port multiposition valve and an internal magnetic stir bar enables precise mixing, bead dispersion, and magnetic capture for consistent bioconjugate synthesis. The LIS platform achieved a 99.6% bead recovery with 0.4 mg of MIS (1 μm in diameter), outperforming the 83% recovery of manual techniques, and maintained an 83% recovery at reduced scales of 0.2 mg, surpassing manual yields of 76%. As a proof-of-concept, MIS conjugated with anti-SARS-CoV2 antibodies (6 μg/400 mg beads) were synthesized and validated for viral RNA isolation from COVID-19-positive samples, demonstrating high immunocapture efficiency comparable to manual methods but with significantly reduced time and labor requirements. This automated synthesis of antibody-MIS enables the scalable, reproducible production of bioconjugated materials, supporting advanced applications in diagnostic assays, therapeutic delivery, and microfluidic integrations. The LIS approach thus enhances the scope of biomolecular conjugate synthesis, offering streamlined workflows that are suited for downstream analytical and bioanalytical applications. LIS is a versatile, automated system for preparing MIS that researchers can adapt for various targets, particularly when commercial products are unavailable, are prohibitively expensive, or require custom carriers.